Fibroblast growth factor 23: State of the field and future directions

Trends in Endocrinology and Metabolism

Volumn 23, Issue 12, 2012, Pages 610-618

  Bhattacharyya, Nisan ^a   Chong, William H ^a   Gafni, Rachel I ^a   Collins, Michael T ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; FIBROBLAST GROWTH FACTOR 23; FURIN; IRON; PROTEIN GALNT3; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; BONE FRAGILITY; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE MUTATION; HYPOXIA; METABOLIC DISORDER; MINERAL METABOLISM; MORBIDITY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; IRON METABOLISM DISORDERS; KIDNEY DISEASES; MICE; RECEPTORS, FIBROBLAST GROWTH FACTOR; VITAMIN D;

EID: 84869496668     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.07.002     Document Type: Review

References (100)

1. Yamashita T., et al. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem. Biophys. Res. Commun. 2000, 277:494-498.
2. Liu S., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 2006, 17:1305-1315.
3. Barthel T.K., et al. 1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J. Steroid Biochem. Mol. Biol. 2007, 103:381-388.
4. Shimada T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:6500-6505.
5. ADHR Consortium Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 2000, 26:345-348.
6. Yamazaki Y., et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J. Bone Miner. Res. 2008, 23:1509-1518.
7. Goetz R., et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol. 2007, 27:3417-3428.
8. Frishberg Y., et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J. Bone Miner. Res. 2007, 22:235-242.
9. Goetz R., et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc. Natl. Acad. Sci. U.S.A. 2009, 107:407-412.
10. Berndt T., et al. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:11085-11090.
11. Topaz O., et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat. Genet. 2004, 36:579-581.
12. Kato K., et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J. Biol. Chem. 2006, 281:18370-18377.
13. Bergwitz C., et al. Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis. J. Clin. Endocrinol. Metab. 2009, 94:4267-4274.
14. Chefetz I., Sprecher E. Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis. Biochim. Biophys. Acta 2009, 1792:847-852.
15. Collins M.T., et al. Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J. Bone Miner. Res. 2001, 16:806-813.
16. Riminucci M., et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 2003, 112:683-692.
17. Sitara D., et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004, 23:421-432.
18. Mirams M., et al. Bone as a source of FGF23: regulation by phosphate?. Bone 2004, 35:1192-1199.
19. Onishi T., et al. Phex mutation causes overexpression of FGF23 in teeth. Arch. Oral Biol. 2008, 53:99-104.
20. Prader A., et al. Rickets following bone tumor. Helv. Paediatr. Acta 1959, 14:554-565. (in German).
21. Cai Q., et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N. Engl. J. Med. 1994, 330:1645-1649.
22. Chong W.H., et al. Tumor-induced osteomalacia. Endocr. Relat. Cancer 2011, 18:R53-R77.
23. Folpe A.L., et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am. J. Surg. Pathol. 2004, 28:1-30.
24. Sethi S.K., et al. Elevated FGF-23 and parathormone in linear nevus sebaceous syndrome with resistant rickets. Pediatr. Nephrol. 2010, 25:1577-1578.
25. Boyce A.M., et al. A novel syndrome of neurocutaneous melanosis, hypophosphatemic rickets, and a mosaic skeletal dysplasia. Endocr. Rev. 2011, 32:P2-P162.
26. Imel E.A., et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 2006, 91:2055-2061.
27. Khosravi A., et al. Determination of the elimination half-life of fibroblast growth factor-23. J. Clin. Endocrinol. Metab. 2007, 92:2374-2377.
28. Stubbs J.R., et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J. Bone Miner. Res. 2012, 27:38-46.
29. Isakova T., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011, 79:1370-1378.
30. Shimada T., et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J. Clin. Endocrinol. Metab. 2010, 95:578-585.
31. Larsson T., et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003, 64:2272-2279.
32. Urakawa I., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006, 444:770-774.
33. Kurosu H., et al. Regulation of fibroblast growth factor-23 signaling by klotho. J. Biol. Chem. 2006, 281:6120-6123.
34. Razzaque M.S. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat. Rev. 2009, 5:611-619.
35. Faul C., et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 2011, 121:4393-4408.
36. Gutierrez O.M., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008, 359:584-592.
37. 2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am. J. Physiol. Renal Physiol. 2011, 301:F371-F377.
38. Gupta A., et al. FGF-23 is elevated by chronic hyperphosphatemia. J. Clin. Endocrinol. Metab. 2004, 89:4489-4492.
39. Geller J.L., et al. Cinacalcet in the management of tumor-induced osteomalacia. J. Bone Miner. Res. 2007, 22:931-937.
40. Alon U.S., et al. Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin. J. Am. Soc. Nephrol. 2008, 3:658-664.
41. Weinman E.J., et al. Fibroblast growth factor-23-mediated inhibition of renal phosphate transport in mice requires sodium-hydrogen exchanger regulatory factor-1 (NHERF-1) and synergizes with parathyroid hormone. J. Biol. Chem. 2011, 286:37216-37221.
42. + exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling. Nature 2002, 417:858-861.
43. Baum M., et al. Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int. 2005, 68:1148-1153.
44. Shimada T., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 2004, 19:429-435.
45. Shimada T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 2004, 113:561-568.
46. Farrow E.G., et al. Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J. Am. Soc. Nephrol. 2009, 20:955-960.
47. Ben-Dov I.Z., et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 2007, 117:4003-4008.
48. Krajisnik T., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J. Endocrinol. 2007, 195:125-131.
49. Ichikawa S., et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J. Clin. Invest. 2007, 117:2684-2691.
50. Antoniucci D.M., et al. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J. Clin. Endocrinol. Metab. 2006, 91:3144-3149.
51. Burnett S.A., et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J. Bone Miner. Res. 2006, 21:1187-1196.
52. Ferrari S.L., et al. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab. 2005, 90:1519-1524.
53. Yu X., et al. Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 2005, 36:971-977.
54. Collins M.T., et al. Fibroblast growth factor-23 is regulated by 1alpha, 25-dihydroxyvitamin D. J. Bone Miner. Res. 2005, 20:1944-1950.
55. Kolek O.I., et al. 1alpha, 25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G1036-G1042.
56. Brown W.W., et al. Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J. Clin. Endocrinol. Metab. 2009, 94:17-20.
57. Singh R.J., Kumar R. Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and hyperparathyroidism. Mayo Clin. Proc. 2003, 78:826-829.
58. Tebben P.J., et al. Fibroblast growth factor 23, parathyroid hormone, and 1alpha, 25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin. Proc. 2004, 79:1508-1513.
59. Kobayashi K., et al. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur. J. Endocrinol. 2006, 154:93-99.
60. Kawata T., et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J. Am. Soc. Nephrol. 2007, 18:2683-2688.
61. Mosekilde L. Primary hyperparathyroidism and the skeleton. Clin. Endocrinol. (Oxf.) 2008, 69:1-19.
62. Benet-Pages A., et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 2005, 14:385-390.
63. Chefetz I., et al. A novel homozygous missense mutation in FGF23 causes familial tumoral calcinosis associated with disseminated visceral calcification. Hum. Genet. 2005, 118:261-266.
64. Dumitrescu C.E., et al. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features. Osteoporos. Int. 2009, 20:1273-1278.
65. Feng J.Q., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 2006, 38:1310-1315.
66. Lorenz-Depiereux B., et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat. Genet. 2006, 38:1248-1250.
67. Francis F., et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets The HYP Consortium. Nat. Genet. 1995, 11:130-136.
68. Levy-Litan V., et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am. J. Hum. Genet. 2010, 86:273-278.
69. Quarles L.D. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat. Rev. Endocrinol. 2012, 8:276-286.
70. Durham B.H., et al. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann. Clin. Biochem. 2007, 44:463-466.
71. Schouten B.J., et al. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann. Clin. Biochem. 2009, 46:167-169.
72. Schouten B.J., et al. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J. Clin. Endocrinol. Metab. 2009, 94:2332-2337.
73. Shimizu Y., et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 2009, 45:814-816.
74. Imel E.A., et al. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J. Clin. Endocrinol. Metab. 2011, 96:3541-3549.
75. Farrow E.G., et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:E1146-E1155.
76. Rankin E.B., et al. The HIF signaling pathway in osteoblasts directly modulates erhytropoesis through the production of EPO. Cell 2012, 149:63-74.
77. Bhattacharyya N., et al. Mechanism of FGF23 processing in fibrous dysplasia. J. Bone Miner. Res. 2012, 27:1132-1141.
78. Knutson M.D. Iron-sensing proteins that regulate hepcidin and enteric iron absorption. Annu. Rev. Nutr. 2010, 30:149-171.
79. Mirza M.A., et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009, 205:385-390.
80. Parker B.D., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann. Intern. Med. 2010, 152:640-648.
81. Fuleihan G.E., et al. Racial differences in parathyroid hormone dynamics. J. Clin. Endocrinol. Metab. 1994, 79:1642-1647.
82. Bell N.H., et al. Tight regulation of circulating 1 alpha, 25-dihydroxyvitamin D in black children. N. Engl. J. Med. 1985, 313:1418.
83. Bell N.H., et al. Demonstration of a difference in urinary calcium, not calcium absorption, in black and white adolescents. J. Bone Miner. Res. 1993, 8:1111-1115.
84. Cosman F., et al. Resistance to bone resorbing effects of PTH in black women. J. Bone Miner. Res. 1997, 12:958-966.
85. Mirza M.A., et al. Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J. Bone Miner. Res. 2011, 26:857-864.
86. Carpenter T.O., et al. A clinician's guide to X-linked hypophosphatemia. J. Bone Miner. Res. 2011, 26:1381-1388.
87. Turan S., et al. Identification of a novel dentin matrix protein-1 (DMP-1) mutation and dental anomalies in a kindred with autosomal recessive hypophosphatemia. Bone 2010, 46:402-409.
88. Lorenz-Depiereux B., et al. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am. J. Hum. Genet. 2010, 86:267-272.
89. Mehta P., et al. Novel compound heterozygous mutations in ENPP1 cause hypophosphataemic rickets with anterior spinal ligament ossification. Rheumatology (Oxford) 2012, 10.1093/rheumatology/kes089.
90. Saito T., et al. A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. Bone 2011, 49:913-916.
91. Brownstein C.A., et al. A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3455-3460.
92. Jan de Beur S.M. Tumor-induced osteomalacia. JAMA 2005, 294:1260-1267.
93. Dumitrescu C.E., Collins M.T. McCune-Albright syndrome. Orphanet J. Rare Dis. 2008, 3:12.
94. Collins M.T., et al. McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. Orphanet J. Rare Dis. 2012, 7(Suppl. 1):S4.
95. White K.E., et al. Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am. J. Hum. Genet. 2005, 76:361-367.
96. Benet-Pages A., et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 2004, 14:385-390.
97. Narchi H. Hyperostosis with hyperphosphatemia: evidence of familial occurrence and association with tumoral calcinosis. Pediatrics 1997, 99:745-748.
98. Frishberg Y., et al. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. J. Mol. Med. (Berlin, Germany) 2005, 83:33-38.
99. Meyer R.A., et al. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J. Bone Miner. Res. 1989, 4:493-500.
100. Weber T.J., et al. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J. Bone Miner. Res. 2003, 18:1227-1234.